[go: up one dir, main page]

NO20082181L - Formuleringer av Fispemifen - Google Patents

Formuleringer av Fispemifen

Info

Publication number
NO20082181L
NO20082181L NO20082181A NO20082181A NO20082181L NO 20082181 L NO20082181 L NO 20082181L NO 20082181 A NO20082181 A NO 20082181A NO 20082181 A NO20082181 A NO 20082181A NO 20082181 L NO20082181 L NO 20082181L
Authority
NO
Norway
Prior art keywords
pharmaceutically acceptable
fispemifen
formulations
stereoisomer
metabolite
Prior art date
Application number
NO20082181A
Other languages
English (en)
Norwegian (no)
Inventor
Veli-Matti Lehtola
Kaija Halonen
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of NO20082181L publication Critical patent/NO20082181L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20082181A 2005-11-09 2008-05-13 Formuleringer av Fispemifen NO20082181L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73493505P 2005-11-09 2005-11-09
PCT/IB2006/004240 WO2007099410A2 (fr) 2005-11-09 2006-11-09 Formulations de fispemifène

Publications (1)

Publication Number Publication Date
NO20082181L true NO20082181L (no) 2008-05-27

Family

ID=38459402

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082181A NO20082181L (no) 2005-11-09 2008-05-13 Formuleringer av Fispemifen

Country Status (11)

Country Link
US (1) US20070104743A1 (fr)
EP (1) EP1948148A2 (fr)
JP (1) JP2009514944A (fr)
KR (1) KR20080075157A (fr)
CN (1) CN101304738A (fr)
AU (1) AU2006339325A1 (fr)
BR (1) BRPI0618510A2 (fr)
CA (1) CA2628964A1 (fr)
NO (1) NO20082181L (fr)
RU (1) RU2008122993A (fr)
WO (1) WO2007099410A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
EP2494958A1 (fr) 2006-12-01 2012-09-05 Anterios, Inc. Nanoparticules d'entité amphiphile
CA2671133C (fr) 2006-12-01 2015-11-24 Anterios, Inc. Nanoparticules peptidiques et utilisations de celles-ci
US10016451B2 (en) 2007-05-31 2018-07-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
WO2008157335A2 (fr) * 2007-06-13 2008-12-24 Quatrx Pharmaceuticals Company Procédés de traitement d'un dysfonctionnement érectile en utilisant du fispémifène
KR20100135857A (ko) * 2008-03-28 2010-12-27 유니버시티 오브 매사추세츠 나노에멀젼의 제조를 위한 조성물 및 방법
KR20160130519A (ko) * 2008-06-26 2016-11-11 안테리오스, 인코퍼레이티드 경피 운반
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US6261812B1 (en) * 1997-08-18 2001-07-17 Kao Corporation Process for producing diglycerides
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
TW593256B (en) * 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
HRP20040547A2 (en) * 2001-11-29 2005-08-31 Gtx Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
US20040248989A1 (en) * 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
JP2007523952A (ja) * 2004-02-25 2007-08-23 スミスクライン ビーチャム コーポレーション 選択的エストロゲンレセプターモジュレーターとして使用するための置換キノリン化合物
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene

Also Published As

Publication number Publication date
CA2628964A1 (fr) 2007-09-07
BRPI0618510A2 (pt) 2011-09-06
WO2007099410A2 (fr) 2007-09-07
KR20080075157A (ko) 2008-08-14
AU2006339325A1 (en) 2007-09-07
RU2008122993A (ru) 2009-12-20
US20070104743A1 (en) 2007-05-10
CN101304738A (zh) 2008-11-12
JP2009514944A (ja) 2009-04-09
EP1948148A2 (fr) 2008-07-30
WO2007099410A3 (fr) 2008-04-17

Similar Documents

Publication Publication Date Title
NO20082181L (no) Formuleringer av Fispemifen
NO20064262L (no) Fast formulering av ospemifen
NO20043367L (no) Oralt farmasoytisk preparat
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
RU2008139315A (ru) Избирательные андрогенные рецепторные модуляторы
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
LU92736I2 (fr) Ospémifène dans toutes les formes protégées par lebrevet de base
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
JP2013519653A5 (fr)
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
WO2009007137A3 (fr) Composition pharmaceutique pour application topique de composés difficilement solubles
UA101407C2 (ru) Стабильная комбинированная фармацевтическая композиция амлодипина и бисопролола фумарат
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
SE0401655D0 (sv) New compounds
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
MX342824B (es) Nuevos compuestos de triazol iii.
NO20065074L (no) Nye orale formuleringer av ospemifen.
GT200500214A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon
TR200802061A2 (tr) Yüksek oranda aktif madde içeren farmasötlk formülasyon.
GB0322994D0 (en) Organic compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application